Zhejiang East Asia Pharmaceutical Co., Ltd.

Primary objective: To investigate the in vivo pharmacokinetic characteristics of Tedizolid Phosphate Tablets (Specification: 200 mg) produced by Zhejiang East Asia Pharmaceutical Co., Ltd. and Tedizolid Phosphate Tablets (trade name: SIVEXTRO®; specification: 200 mg) produced by MSD Pharma (Singapore) Pte Ltd and manufactured by Patheon Inc. after a single oral dose in healthy Chinese subjects under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test preparation (specification: 200 mg) and reference preparation (trade name: SIVEXTRO®; specification: 200 mg) of Tedizolid Phosphate Tablets in healthy Chinese subjects after a single oral dose.

Main objective: To use epalrestat tablets provided by Zhejiang East Asia Pharmaceutical Co., Ltd. as the test preparation and compare their absorption rate and extent in healthy humans with those of epalrestat tablets (trade name: KINEDAK®, reference preparation) certified by Alpharestat Pharmaceuticals Co., Ltd. according to the relevant provisions of bioequivalence studies, and to investigate the bioequivalence of the two preparations in humans.

Main purpose of study: According to the relevant provisions of bioequivalence test, Takeda Pharmaceutical Company Limited was selected as the reference preparation for the human bioequivalence test of vonoprazan fumarate tablets (trade name: Vocinti (Walker), specification: 20mg), and the test preparation vonoprazan fumarate tablets (specification: 20mg) produced by Zhejiang East Asia Pharmaceutical Co., Ltd. was used for fasting and postprandial administration. The absorption rate and degree of the drug in the test preparation were compared with the reference preparation to see whether they were within the acceptable range, and the bioequivalence of the two preparations under fasting and postprandial administration conditions was evaluated. Secondary purpose of study: To observe the safety of oral administration of the test preparation vonoprazan fumarate tablets (specification: 20mg) and the reference preparation vonoprazan fumarate tablets (trade name: Vocinti (Walker), specification: 20mg) in healthy subjects.